CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Comparison of paclitaxel-eluting stents (Taxus) and everolimus-eluting stents (Xience) in left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM registry) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Suture- or Plug-Based Large-Bore Arteriotomy Closure: A Pilot Randomized Controlled Trial Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older Dilated cardiomyopathy: so many cardiomyopathies! 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association Increased glycated albumin and decreased esRAGE levels in serum are related to negative coronary artery remodeling in patients with type 2 diabetes: an Intravascular ultrasound study A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
|<<... 89 90 91 92 93 94 95 ...>>|

Original Research2018 Jun 5;71(22):2497-2506.

JOURNAL：J Am Coll Cardiol. Article Link

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL

Cavender MA, Norhammar A, CVD-REAL Investigators and Study Group. Keywords: CVD-REAL; cardiovascular disease; heart failure; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top